Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 431

1.

Cardiotoxicity of novel HER2-targeted therapies.

Sendur MA, Aksoy S, Altundag K.

Curr Med Res Opin. 2013 Aug;29(8):1015-24. doi: 10.1185/03007995.2013.807232. Epub 2013 Jun 7. Review.

PMID:
23692263
2.

Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer.

Boyraz B, Sendur MA, Aksoy S, Babacan T, Roach EC, Kizilarslanoglu MC, Petekkaya I, Altundag K.

Curr Med Res Opin. 2013 Apr;29(4):405-14. doi: 10.1185/03007995.2013.775113. Epub 2013 Mar 1. Review.

PMID:
23402224
3.

Pertuzumab in HER2-positive breast cancer.

Sendur MA, Aksoy S, Altundag K.

Curr Med Res Opin. 2012 Oct;28(10):1709-16. doi: 10.1185/03007995.2012.728132. Epub 2012 Oct 11. Review.

PMID:
22953713
4.

Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer.

Barginear MF, John V, Budman DR.

Mol Med. 2013 Jan 22;18:1473-9. doi: 10.2119/molmed.2012.00302.

5.

A systematic review of dual targeting in HER2-positive breast cancer.

Kümler I, Tuxen MK, Nielsen DL.

Cancer Treat Rev. 2014 Mar;40(2):259-70. doi: 10.1016/j.ctrv.2013.09.002. Epub 2013 Sep 11. Review.

PMID:
24080156
6.

Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.

De Mattos-Arruda L, Cortes J.

Adv Ther. 2013 Jul;30(7):645-58. doi: 10.1007/s12325-013-0043-2. Epub 2013 Jul 24. Review.

PMID:
23881722
7.

Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.

Corrigan PA, Cicci TA, Auten JJ, Lowe DK.

Ann Pharmacother. 2014 Nov;48(11):1484-93. doi: 10.1177/1060028014545354. Epub 2014 Jul 31. Review.

PMID:
25082874
8.

Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.

Krop I, Winer EP.

Clin Cancer Res. 2014 Jan 1;20(1):15-20. doi: 10.1158/1078-0432.CCR-13-0541. Epub 2013 Oct 17.

9.

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K; EMILIA Study Group.

N Engl J Med. 2012 Nov 8;367(19):1783-91. doi: 10.1056/NEJMoa1209124. Epub 2012 Oct 1. Erratum in: N Engl J Med. 2013 Jun 20;368(25):2442.

10.

Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.

Phillips GD, Fields CT, Li G, Dowbenko D, Schaefer G, Miller K, Andre F, Burris HA 3rd, Albain KS, Harbeck N, Dieras V, Crivellari D, Fang L, Guardino E, Olsen SR, Crocker LM, Sliwkowski MX.

Clin Cancer Res. 2014 Jan 15;20(2):456-68. doi: 10.1158/1078-0432.CCR-13-0358. Epub 2013 Oct 4.

11.

Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis.

Yu Q, Zhu Z, Liu Y, Zhang J, Li K.

PLoS One. 2015 May 20;10(5):e0127404. doi: 10.1371/journal.pone.0127404. eCollection 2015.

12.
13.

Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine.

Sadeghi S, Olevsky O, Hurvitz SA.

Pharmgenomics Pers Med. 2014 Oct 15;7:329-38. doi: 10.2147/PGPM.S47524. eCollection 2014. Review.

14.

Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer.

Haddley K.

Drugs Today (Barc). 2013 Nov;49(11):701-15. doi: 10.1358/dot.2013.49.11.2020937. Review.

PMID:
24308017
15.

Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates.

Wong DJ, Hurvitz SA.

Ann Transl Med. 2014 Dec;2(12):122. doi: 10.3978/j.issn.2305-5839.2014.08.13. Review.

16.

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.

Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, Guardino E, Lu M, Zheng M, Girish S, Amler L, Winer EP, Rugo HS.

J Clin Oncol. 2012 Sep 10;30(26):3234-41. doi: 10.1200/JCO.2011.40.5902. Epub 2012 May 29.

17.

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.

Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, Amler L, Zheng M, Chu YW, Klencke B, O'Shaughnessy JA.

J Clin Oncol. 2011 Feb 1;29(4):398-405. doi: 10.1200/JCO.2010.29.5865. Epub 2010 Dec 20.

18.

Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.

Burris HA.

Expert Opin Biol Ther. 2011 Jun;11(6):807-19. doi: 10.1517/14712598.2011.580273. Epub 2011 Apr 21.

PMID:
21506905
19.

Anti-HER2 cancer therapy and cardiotoxicity.

Babar T, Blomberg C, Hoffner E, Yan X.

Curr Pharm Des. 2014;20(30):4911-9. Review.

PMID:
24898245
20.

Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer.

Chung C, Lam MS.

Am J Health Syst Pharm. 2013 Sep 15;70(18):1579-87. doi: 10.2146/ajhp120735. Review.

PMID:
23988598
Items per page

Supplemental Content

Write to the Help Desk